"Dec. 2, 2010 -- Babies born to women who take the antiseizure drug carbamazepine have a more than twofold increased risk for the birth defect spina bifida, a study shows.
But researchers say the drug still has less risk of birth defects"...
Stavzor Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Stavzor (valproic acid) Delayed Release Capsules is used to treat various types of seizure disorders, manic episodes associated with bipolar disorder, and to prevent migraine headaches. Common side effects include drowsiness or weakness, diarrhea, constipation, upset stomach, changes in menstrual periods, enlarged breasts, tremor (shaking), hair loss, weight changes, vision changes, or unusual or unpleasant taste in your mouth.
Dosage of Stavzor depends on the condition being treated. Stavzor may interact with topiramate, tolbutamide, blood thinners, aspirin or acetaminophen (Tylenol), zidovudine, clozapine, diazepam, meropenem or imipenem and cilastatin, rifampin, ethosuximide, cold or allergy medicine, narcotics, sleeping pills, muscle relaxers, and medicine for depression or anxiety. Tell your doctor all medications and supplements you use. Stavzor can cause birth defects. Do not start taking Stavzor without telling your doctor if you are pregnant or planning to become pregnant. Use birth control while taking Stavzor. Having a seizure during pregnancy could harm both mother and baby. If you become pregnant while taking Stavzor, do not stop taking the medicine without your doctor's advice. This drug passes into breast milk and may harm a nursing baby. Do not breastfeed while taking Stavzor.
Our Stavzor (valproic acid) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Stavzor in Detail - Patient Information: Side Effects
Seek emergency medical attention if the person taking this medicine has nausea, vomiting, upper stomach pain, or loss of appetite, low fever, dark urine, clay-colored stools, or jaundice (yellowing of the skin or eyes). These symptoms may be early signs of liver damage. Some of these symptoms may also be early signs of pancreatitis.
Report any new or worsening symptoms to your doctor, such as: mood or behavior changes, anxiety, panic attacks, trouble sleeping, or if you feel impulsive, irritable, agitated, hostile, aggressive, restless, hyperactive (mentally or physically), more depressed, or have thoughts about suicide or hurting yourself.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these other serious side effects:
- unexplained weakness with vomiting and confusion or fainting;
- easy bruising or bleeding, blood in your urine;
- fever, chills, body aches, swollen glands, flu symptoms;
- urinating less than usual;
- hallucinations (seeing things that aren't there);
- extreme drowsiness, lack of coordination;
- double vision or back-and-forth movements of the eyes; or
- severe skin reaction -- fever, sore throat, swelling in your face or tongue, burning in your eyes, skin pain, followed by a red or purple skin rash that spreads (especially in the face or upper body) and causes blistering and peeling.
Less serious side effects may include:
- mild drowsiness or weakness;
- diarrhea, constipation, upset stomach;
- changes in your menstrual periods;
- enlarged breasts;
- tremor (shaking);
- hair loss;
- weight changes;
- vision changes; or
- unusual or unpleasant taste in your mouth.
Read the entire detailed patient monograph for Stavzor (Valproic Acid) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Stavzor FDA Prescribing Information: Side Effects
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
The incidence of adverse reactions has been ascertained based on combined data from 2 placebo-controlled clinical trials of valproate in the treatment of manic episodes associated with bipolar disorder. The adverse reactions were usually mild or moderate in intensity, but sometimes were serious enough to interrupt treatment. In clinical trials, the rates of premature termination due to intolerance were not statistically different between placebo, valproate, and lithium carbonate. A total of 4%, 8% and 11% of patients discontinued therapy due to intolerance in the placebo, valproate, and lithium carbonate groups, respectively.
Table 2 summarizes those adverse reactions reported for patients in these trials where the incidence rate in the valproate -treated group was greater than 5% and greater than the placebo incidence, or where the incidence in the valproate -treated group was statistically significantly greater than the placebo group. Vomiting was the only event that was reported by significantly (p ≤ 0.05) more patients receiving valproate compared to placebo.
Table 2: Adverse Reactions Reported by > 5% of
Valproate-Treated Patients During Placebo-Controlled Trials of Acute Maniaa
|a The following adverse reactions occurred at an equal or greater incidence for placebo than for valproate: back pain, headache, constipation, diarrhea, tremor, and pharyngitis.|
The following additional adverse reactions were reported by greater than 1% but not more than 5% of the 89 valproate-treated patients in controlled clinical trials:
Body as a Whole: Chest pain, chills, chills and fever, fever, neck pain, neck rigidity. Cardiovascular System: Hypertension, hypotension, palpitations, postural hypotension, tachycardia, vasodilation.
Hemic and Lymphatic System: Ecchymosis.
Metabolic and Nutritional Disorders: Edema, peripheral edema.
Nervous System: Abnormal dreams, abnormal gait, agitation, ataxia, catatonic reaction, confusion, depression, diplopia, dysarthria, hallucinations, hypertonia, hypokinesia, insomnia, paresthesia, reflexes increased, tardive dyskinesia, thinking abnormalities, vertigo.
Based on a placebo-controlled trial of adjunctive therapy for treatment of complex partial seizures, valproate was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Intolerance was the primary reason for discontinuation in the valproate -treated patients (6%), compared to 1% of placebo-treated patients.
Table 3 lists treatment-emergent adverse reactions which were reported by ≥ 5% of valproate -treated patients and for which the incidence was greater than in the placebo group, in the placebo-controlled trial of adjunctive therapy for treatment of complex partial seizures. Since patients were also treated with other antiepilepsy drugs, it is not possible, in most cases, to determine whether the following adverse reactions can be ascribed to valproate alone, or the combination of valproate and other antiepilepsy drugs.
Table 3: Adverse Reactions Reported by > 5% of
Patients Treated with Valproate During Placebo-Controlled Trial of Adjunctive
Therapy for Complex Partial Seizures
|Body System/Event||Valproate (%)
(n = 77)
(n = 70)
|Body as a Whole|
Table 4 lists treatment-emergent adverse reactions which were reported by ≥ 5% of patients in the high dose valproate group, and for which the incidence was greater than in the low dose group, in a controlled trial of valproate monotherapy treatment of complex partial seizures. Since patients were being titrated off another antiepilepsy drug during the first portion of the trial, it is not possible, in many cases, to determine whether the following adverse reactions can be ascribed to valproate alone, or the combination of valproate and other antiepilepsy drugs.
Table 4: Adverse Reactions
Reported by > 5% of Patients in the High-Dose Group in the Controlled Trial
of Valproate Monotherapy for Complex Partial Seizuresa
|Body System/Event||High Dose (%)
(n = 131)
|Low Dose (%)
(n = 134)
|Body as a Whole|
|Thromb ocy topenia||24||1|
|Skin and Appendages|
|aHeadache was the only adverse event that occurred in ≥ 5% of patients in the high-dose group and at an equal or greater incidence in the low-dose group.|
The following additional adverse reactions were reported by greater than 1% but less than 5% of the 358 patients treated with valproate in the controlled trials of complex partial seizures:
Body as a Whole: Back pain, chest pain, malaise.
Cardiovascular System: Tachycardia, hypertension, palpitation.
Hemic and Lymphatic System: Petechia.
Musculoskeletal System: Myalgia, twitching, arthralgia, leg cramps, myasthenia.
Nervous System: Anxiety, confusion, abnormal gait, paresthesia, hypertonia, incoordination, abnormal dreams, personality disorder.
Skin and Appendages: Rash, pruritus, dry skin.
Special Senses: Taste perversion, abnormal vision, deafness, otitis media.
Based on 2 placebo-controlled clinical trials and their long-term extension, valproate was generally well tolerated with most adverse reactions rated as mild to moderate in severity. Of the 202 patients exposed to valproate in the placebo-controlled trials, 17% discontinued for intolerance. This is compared to a rate of 5% for the 81 placebo patients. Including the long-term extension study, the adverse reactions reported as the primary reason for discontinuation by ≥ 1% of 248 valproate-treated patients were alopecia (6%), nausea and/or vomiting (5%), weight gain (2%), tremor (2%), somnolence (1%), elevated SGOT and/or SGPT (1%), and depression (1%).
Table 5 includes those adverse reactions reported for patients in the placebo-controlled trials where the incidence rate in the valproate-treated group was greater than 5% and was greater than that for placebo patients.
Table 5: Adverse Reactions
Reported by > 5% of Valproate-Treated Patients During Migraine Placebo-Controlled
Trials With a Greater Incidence Than Patients Taking Placeboa
|Body System Event||Valproate
The following additional adverse reactions were reported by greater than 1% but not more than 5% of the 202 valproate-treated patients in the controlled clinical trials:
Body as a Whole: Chest pain, chills, face edema, fever and malaise.
Cardiovascular System: Vasodilatation.
Hemic and Lymphatic System: Ecchymosis.
Metabolic and Nutritional Disorders: Peripheral edema, SGOT increase, and SGPT increase.
Musculoskeletal System: Leg cramps and myalgia.
Respiratory System: Cough increased, dyspnea, rhinitis, and sinusitis.
Skin and Appendages: Pruritus and rash.
Special Senses: Conjunctivitis, ear disorder, taste perversion, and tinnitus.
Post Marketing Experience
The following adverse reactions have been identified during post approval use of STAVZOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Hematologic: Relative lymphocytosis, macrocytosis, hypofibrinogenemia, leukopenia, eosinophilia, anemia including macrocytic with or without folate deficiency, bone marrow suppression, pancytopenia, aplastic anemia, agranulocytosis, and acute intermittent porphyria.
Endocrine: Irregular menses, secondary amenorrhea, breast enlargement, galactorrhea, polycystic ovary disease, and parotid gland swelling, decreased carnitine concentrations, hyponatremia, hyperglycinemia, and inappropriate ADH secretion.
Special Senses: Hearing loss.
Read the entire FDA prescribing information for Stavzor (Valproic Acid) »
Additional Stavzor Information
Report Problems to the Food and Drug Administration
Get tips on therapy and treatment.